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1.  IntroductIon
Yellow fever is an important hemorrhagic arboviral 
infection reported from many parts of Africa and central South 
America. It is categorised under category ‘C’ of potential 
bioterrorism agent under NIAID list1. It is also included 
under the export control list of Australia Group2. This is a 
zoonotic disease, transmitted by both sylvatic and urban cycle. 
In sylvatic cycle, the transmission occurs between Aedes 
mosquitoes and monkey in the forest, as monkeys are the main 
reservoirs. In urban areas, Ae. aegypti mosquitoes transmit 
the virus to humans3,4. An estimated 200,000 cases of yellow 
fever occurs each year worldwide, with the case-fatality rate of 
~15 per cent5. From 1700 to early 1900, YF outbreaks were 
recorded, however close study of this disease was done during 
Spanish-American War and construction of the Panama Canal 
in late 19th century6. YFV is the prototype virus of genus 
Flavivirus in family Flaviviridae. It is a small, enveloped virus 
that contains a single positive strand RNA as its genome, which 
is ~11 kb in size. It encodes a single ORF that consists of three 
structural and seven non structural proteins in the following 
order: 5’ -C-prM(M)-E-NS1-NS2A-NS2B-NS3-NS4A-NS4B-
NS5-3’7. 
Most of the YF infections are asymptomatic, but in some 
cases, there is fever, muscle pain, headache and vomiting are 
reported. However severe illness involves jaundice, abdominal 
pain and haemorrhagic manifestations, which may lead to death 
after 10-14 days of the onset of illness8. There is no specific anti-
viral therapy against YFV except the YF 17D vaccine. This is 
a live attenuated formulation, which is safe and affordable and 
has been in practice since 1940s. During the initial passages, 
this strain was neurotropic, which lost its pathogenicity at 114th 
passage for both mice and monkeys6. The vaccine provides 
immunity within a week to 95 per cent of vaccinees. Long 
lasting protection (>30 yrs) against YFV can be obtained 
through a single dose of this vaccine with rare side effects5. 
According to CDC, YF vaccination is not recommended in 
areas, involving low potential for YFV. It should be considered 
for travellers that are travelling to YFV endemic areas, or when 
travelling to areas that are heavily exposed with mosquitoes9. 
Government of India recommends the vaccination for Indians 
travelling to the endemic countries of Africa and South America. 
The vaccine virus replicate slowly in humans, leading to a 
risk of transmission from vaccinees to mosquitoes, which can 
further replicate within the mosquitoes and can be potentially 
transmitted to naïve individuals. Therefore, there is a need 
to evaluate the replication and transmission efficiency of the 
Indian Ae. aegypti mosquitoes to transmit YF 17D vaccine. In 
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view of this, Indian Ae. aegypti were orally infected with YF 
17D vaccine virus and their potential to allow replication and 
transmission of YFV was assessed.
2.  MAterIAlS And MethodS 
2.1 Adaptation and Propagation of YFV 17d 
Vaccine Strain 
Lyophilised Yellow fever virus vaccine 17 D-204 
(STAMARIL®, Sanofi Pasteur, France) was reconstituted in 
0.5 ml of eagles minimum essential medium (EMEM) (Sigma, 
USA), aliquoted and stored in -80 °C until use. C6/36 cells 
(clone of Ae. albopictus midgut epithelial cells) were obtained 
from NCCS, Pune was maintained at Virology Division, 
Defence Research & Development Establishment (DRDE), 
Gwalior, India. C6/36 cells were seeded in 75 cm2 flask to 
75–80 per cent confluency. Cells were washed with PBS and 
infected with 100 μl volume of reconstituted vaccine virus. 
The virus was allowed to be adsorbed for 2 hrs at 37 °C with 
intermittent shaking in an incubator without CO2. Following 
adsorption, cells were washed with PBS. Fresh EMEM 
medium containing 2 per cent FBS was added and cells were 
incubated at 32 °C for 5 days up to the appearance of CPE. Cell 
control was kept alongside. After visualisation of CPE, cells 
were freeze-thawed and supernatant was harvested, filtered, 
aliquoted and stored at -80 °C for further use. The process was 
repeated twice and the virus at passage level 3 (P3) was used 
for further study.
2.2 titration of YFV
Virus was harvested on 5 dpi and titrated through plaque 
assay in Vero cells (African green monkey kidney cells). For 
this, Vero cells were seeded in 24 well plate (Greiner Bio-
one, Germany). After 24 hrs, medium was gently aspirated 
and cells were washed with PBS. Serial 10-fold dilutions 
of virus were prepared in EMEM and then Vero cells were 
infected with particular virus dilution in triplicate. After 2 hrs 
of virus adsorption, the medium was aspirated and replaced 
with overlay medium containing EMEM, 1.25 per cent 
methylcellulose, 2 per cent FBS and incubated for 5 days. 
The medium was removed and cells were fixed with chilled 
methanol. Subsequently, 0.25 per cent crystal violet was added 
to stain the cell monolayer. Plate was rinsed and dried at room 
temperature, and plaques were counted. Number of plaque per 
well was calculated and virus titer in terms of plaque-forming 
units (PFU/ml) was determined.
2.3 Mosquitoes                                                                                                                  
Ae. aegypti used in this study were collected from 
Gwalior district in 2010 and maintained as a colony in Vector 
Management Division, DRDE. The mosquitoes were kept at a 
temperature of 28 ± 2 °C with 70-80 per cent relative humidity 
and 14:10 light:dark photo period. As energy source, 10 per cent 
sucrose solution (soaked in cotton pads) was provided to adult 
mosquitoes and larvae were allowed to feed on yeast tablets.
2.4 oral Infection of YFV 17d Vaccine Strain in 
Ae. Aegypti  Mosquitoes 
Female Ae. aegypti (4-5 days old) were used for oral 
infection experiments. Prior to infectious blood meal, 
mosquitoes were starved for 24 hours, to enhance blood 
feeding. The infectious blood meal was prepared by adding 
1 ml of YFV 17D vaccine in 2 ml of washed rabbit RBC’s. 
ATP was added in the blood meal to a final concentration of 
5 mM. Mosquitoes were orally infected through Hemotek 
feeding membrane using circulating water (maintained at 
37 °C) as described previously10 (Fig. 1). After 45 min of 
feeding, two mosquitoes were collected for titration of imbibed 
virus. Sixteen Ae. aegypti from two independent experiments 
were processed on 7 and 14 dpi to determine infection rates as 
described previously10. 
Figure 1. (a) oral infection set up and (b) closed view.
2.5 Processing of Individual Mosquito and Viral 
rnA extraction
Individual Ae. aegypti mosquito was homogenised in 2 
ml tubes by adding 300 µl of EMEM (Sigma, USA) and 2 
mm stainless steel beads using a Tissue Lyser LT (Qiagen, 
Germany). The mosquito homogenate was then clarified by 
centrifugation at 6000 x g for 10 min. 140 µl of supernatant 
was used for extraction of RNA using QIAamp viral RNA mini 
kit (Qiagen, Germany). The RNA was finally eluted in 50 µl 
elution buffer. RNA from mosquito samples was subjected to 
YFV specific quantitative RT-PCR.
Oral infection and mosquito processing experiments were 
performed in BSL-3 laboratory.
2.6  Quantitative rt-Pcr
The primers for quantitative RT-PCR (qRT-PCR) assay 
were selected from a previously published report that targets 
the junction region of 5′ NTR and capsid gene11. The sequence 
of forward primer is YFS: AATCGAGTTGCTAGGCAATA
AACAC(genomic position: 29–53) and sequence of reverse 
primer is YFAS: TCCCTGAGCTTTACGACCAGA (genomic 
position: 141–121). For detection and quantitation of YFV titer 
in mosquitoes, qRT-PCR was carried out using SS III Platinum 
one step qRT-PCR kit (Invitrogen, USA) in Mx3005P system 
(Stratagene, USA). The reaction was carried out in a 25 µl 
volume. It comprised of 2X Master mix-12.5 µl, 0.25 µmol 
each of forward and reverse primers-0.5 µl (YFS and YFAS), 
enzyme mix (Taq DNA polymerase and reverse transcriptase)-
0.25 µl, nuclease free water-9.87 µl and RNA-2.5 µl. The 
thermal profile consisted of reverse transcription-30 min at 
50 °C, polymerase activation-10 min at 95 °C, followed by 40 
cycles of PCR at 95 °C-30 s, 54 °C-60 s, and 72 °C-30 s. After 
amplification, a melting curve analysis was performed with the 
(a) (b)
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melting curve analysis software of Mx3005P according to the 
manufacturer’s instructions. The RNA copies from Ct values 
were extrapolated using a standard curve reported by Dash12, 
et al.
2.7 Statistics
Sixteen mosquitoes from two independent experiments 
were processed on 7 dpi and 14 dpi to determine infection rates. 
Data is represented as Mean ± Standard deviation (Microsoft 
Excel 2010).
3.  reSultS
3.1 Propagation and titration of YFV
After serial passage of YF 17D vaccine in C6/36 cells, 
YFV was produced. On 5 dpi, minor cytopathic effects like 
granulation, cell clumping were observed. Viral titer was found 
to be 5 × 104 PFU/ml, 8 × 105 PFU/ml, and 4 × 106 PFU/ml 
at P1, P2, and P3 respectively as calculated through plaque 
assay. Cytopathic effect and virus titration of P3 are shown in 
Fig. 2(a) and 2(b), respectively. The virus at P3 was used for 
mosquito oral infection.
Figure 3. YFV titer in YFV 17d, blood meal, 0 day mosquito 
and 7, 14 dpi infected mosquitoes are indicated. 
Figure 2. (a) Propagation of YFV 17d in c6/36 cells. cytopathic 
effect in c6/36 cells at 5 dpi and (b) titration of YFV 
17d by plaque assay in Vero cells.
3.2 Infection rates in Ae. aegypti
For oral infection experiment, 100 mosquitoes were used, 
out  of which 65 mosquitoes were engorged with blood meal. 
From these 65 mosquitoes, 32 mosquitoes (stage 3+)13 were 
selected for infectivity analysis at 7 dpi and 14 dpi. Viral RNA 
titer in blood meal was found to be 4 × 106 RNA copies/ml. Viral 
RNA titer in ‘0’ day mosquito was found to be 4 × 104 RNA copies/
ml in 7 days and 14 days post infected mosquitoes. The infection 
rate of YFV in these mosquitoes was monitored at 7 dpi and 14 
dpi, in which viral RNA copies were not detected in any of the 
Ae. aegypti mosquito, orally infected with YFV vaccine strain, 
as determined through quantitative RT-PCR assay. Thus the 
infection rate was found to be 0 per cent at both 7 dpi and 14 dpi 
(Fig. 3). 
4. dIScuSSIon
Yellow fever virus is the causal agent of yellow fever 
disease. It is endemic to tropical regions of Africa and central 
South America, affecting humans and non-human primates. 
The expansion in the geographical habitats of Ae. aegypti, 
the major vector of YFV,  has led to severe epidemics of fatal 
hemorrhagic disease. Since 1950s, large outbreaks of YFV 
occurred in South America involving Peru, Bolivia, Brazil, 
Colombia, Ecuador. Despite mass vaccination campaigns 
to prevent these outbreaks, major YFV epidemics continued 
to occur14. Resurgence of YFV in South America has been 
attributed to low or incomplete vaccine coverage in endemic 
areas, urbanisation and human migration to forests15. 
Absence of YFV in Asia is an enigma to scientific 
fraternity. Several hypothesis including cross-immunity 
generated in response to other flaviviruses (Dengue and 
Japanese encephalitis virus) or due to low vector competence 
of Asian Ae. aegypti mosquitoes for YFV have been advocated. 
However, none of these have been proven scientifically. 
Increase in international travel and globalisation enhances the 
risk of YFV spread to South and South-East Asian countries 
with tropical climate. Rapid spread of the virus to areas with 
high vector density and naive population like India and other 
South-East Asian countries could potentially occur16. The 
recent introduction and successful establishment of West Nile 
virus, Chikungunya virus and Zika virus in naive territories 
reflects the real threat of arboviral infections.  
Several studies have been performed to analyse the risk 
associated with the transmission of the vaccine strains from 
viremic vaccinees to mosquitoes and then from mosquitoes to 
naive individuals. Only 10 per cent oral infection rates were 
observed in Ae. aegypti from Peurto Rico, while 100 per 
cent infection rates were obtained upon intra-thoracic (IT) 
inoculation17. However, IT route does not demonstrate natural 
infection process as the midgut barriers are bypassed, so this 
does not reflect the actual scenario. 
Besides this, the assessment of vector competence from 
different geographical strains of mosquitoes for different 
viral strains is important to estimate the risks associated with 
potential outbreaks. Vector competence is the susceptibility of a 
(b)
(a)
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vector to oral infection and transmission of a pathogen. Several 
previous reports have demonstrated the vector competence of 
Ae. aegypti from different geographical locations for YFV. 
Australian population of Ae. aegypti was found to be susceptible 
for African strain of YFV as >70 per cent infectivity and 
>50 per cent transmission was achieved. However, the infection 
and transmission rates were lower for South American strains 
of YFV18. Also, Ae. aegypti population from Santa Cruz and 
Bolivia showed infectivity and transmissibility for South 
American YFV strain19. Other vectors like Ae. simpsoni, Ae. 
furcifer are also susceptible to the African YFV suggesting 
the sylvatic mode of transmission between monkeys20. Other 
mechanisms of arboviral transmission in nature is vertical 
transmission i.e. the transmission of virus from infected female 
mosquito to progenies. This is considered as an alternative 
survival mechanism for virus in nature. Vertical transmission 
of YFV by Ae. aegypti was demonstrated naturally from 
field collected male and female mosquitoes21. Experimental 
evidence was provided with Ae. aegypti colonies from Dakar 
and Koungheul that transmitted YFV to male and female 
progenies with increase in infection rates at later oviposition 
cycles22.
In the present study, we evaluated the vector competence 
of YFV 17D vaccine strain for Indian Ae. aegypti mosquitoes. 
Vector competence is greatly affected by oral infectious 
dose (OID) provided to mosquitoes. It has been observed 
that, upon increasing viral dose, infectivity increased in 
mosquitoes23. Therefore a high dose is provided in these 
experiments to maximise the chances of infection. Detection 
and quantification of YFV in YFV 17D vaccine virus was 
performed using a highly sensitive quantitative RT-PCR assay. 
The YFV in infected mosquitoes was titrated as RNA copies 
rather than the infectious virus because of the high sensitivity 
of real time RT-PCR compared to the conventional plaque 
assay. The sensitivity of YFV specific quantitative RT-PCR 
assay employed in this study was found to be high as it has 
a detection limit of 30 RNA copies/reaction12. The infection 
rate of YFV in Ae. aegypti  mosquitoes was monitored at 7 and 
14 dpi. It was observed that none of the Ae. aegypti mosquito 
orally infected with YFV 17D strain was found to be positive 
for YFV. The infection rate was found to be 0 per cent at both 7 
and 14 dpi. Our results are in agreement with a previous report, 
where infection rate was found to be 0 per cent in orally infected 
Ae. aegypti from Thailand24. These results demonstrated the 
inability of the YFV 17D strain to cause infection or replication 
in the midgut epithelial cells of Indian Ae. aegypti, representing 
the negligible risk of YFV spread in India. The inability of 
17D strain to establish infection in midgut led to failure in 
dissemination and further transmission of the YFV. Several 
factors including genetics of both virus and vector along with 
midgut microflora might have attributed to this refractoriness25. 
Further investigations using virulent/epidemic strain of YFV is 
required to evaluate vector competence in Indian Ae. aegypti 
mosquitoes from different geographical locations.
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